- News article -

Bridging the gap for production of nanopharmaceuticals – towards commercialisation of experimental HIV-vaccine

6 Feb 2015

Nine European companies and research institutes combine forces in the NanoPilot-project to create a pilot plant aimed at accelerating the development of nanomedicine by facilitating the production of small clinical batches under Good Manufacturing Practice (GMP). One of the first three nanopharmaceuticals chosen for production in the pilot plant is a promising intranasal HIV vaccine.

A pilot plant capable of producing batches of HIV-vaccine suitable for clinical trials in humans will be set up in the EU-funded NanoPilot-project. The plant will be adapted from existing high-quality laboratories already owned by the project coordinator, Spanish research institute Cidetec. The end goal is to establish a certified plant specialized in the production of clinical batches of polymer-based nanopharmaceuticals, operating under Good Manufacturing Practices (GMP). At the end of the 48-month project, a batch of the HIV vaccine will be produced and shipped to clinical trials.

Despite decades of prevention effort and education, the AIDS epidemic still rampages on. One of the most important reasons for the difficulty of stopping AIDS is the lack of an effective vaccine. With previous studies showing that traditional vaccination approaches are ineffective with HIV, innovative solutions are needed. An intranasal nano-based HIV vaccine has shown positive results in animal studies, and the next step on the road to wide-spread application of the vaccine is clinical trials.

However, for human use, the amount and quality of the vaccine required is vastly different from that of the pre-clinical animal studies. Suitable amounts of GMP quality nanopharmaceuticals cannot be easily produced either in the laboratory or existing pharmaceutical manufacturing plants, which are optimised for the production of large amounts of traditional drugs. The pilot plant set up within the NanoPilot-project aims to fill this gap.

Nanopharmaceutical help for bladder pain and dry eyes

NP-cidetec-photoThe plant will be a flexible and adaptable production facility for small batches of various types of polymer-based nanopharmaceuticals. The versatility of the plant will be demonstrated in two other applications: a nanomedicine for painful bladder syndrome and a novel topical treatment for pain associated with dry eye syndrome. The production process of the three products is differ greatly from one another, which will help demonstrate the flexibility of the pilot plant.

Once completed, the plant will become a vital tool in the commercialisation of nanopharmaceuticals, enabling SMEs and academic institutions to validate their innovations in the field of nanomedicine. SMEs and research institutes are expected to become key players in the development of novel nanodrugs, however, they often lack the resources to upscale the production of their potential nanomedical innovations. The pilot plant established in the NanoPilot project will address this need.

About NanoPilot

The NanoPilot-project is coordinated by the Spanish research institute, Cidetec. The project will combine the efforts of four research institutes and universities: Cidetec, National University of Ireland Galway, Universidad Santiago de Compostela and ADERA-UT2A; three SMEs: iX-Factory, Mejoran and Spinverse; and two large industrial partners, Chemtrix BV and Sylentis, a pharmaceutical company and subsidiary of the Zeltia Group. Spinverse will be partaking in the project by creating and developing the pilot plant’s business plan, and supporting the project’s exploitation and dissemination efforts.

The project started in January 2015 and will continue for 48 months until December 2018, funded by the European Union within the Horizon 2020 framework programme. The total budget of the NanoPilot project is 6,3 MEUR.

Read more on NanoPilot’s website and on nanowerk.com.

Read our reference on NanoPilot!

Photo (c) Cidetec

- Contact us -

Want to learn more how Spinverse could help you? Contact us now!



Satu Ek

Senior Project Manager D.Sc.(Tech.) +358 44 241 7344

- News -

Relevant posts

Public Funding Horizon Europe

When is the first call? Horizon Europe is taking the next steps towards its implementation

21 Oct 2020

We are all waiting for more news on the progress of Horizon Europe, the next big European framework programm...

Ecosystems tackle grand challenges — Spinverse helps them to succeed and create impact!

13 Oct 2020

Spinverse has accumulated years of experience on professionally leading and orchestrating innovation ecosyst...

Public Funding Spinverse News

Economic growth needs innovation and long-term projects — where is the needed public funding?

18 Sep 2020

The Finnish economic success has been based on high-quality education and research. However, Finnish compani...

Public Funding Horizon Europe

Latest news about Horizon Europe and other growth opportunities beyond 2020

16 Sep 2020

Horizon Europe, the EU’s next framework programme for research and innovation, is approaching fast after t...

ecosystem Our People Spinverse News

A must-read: Ecosystem Handbook - The art of leading and creating impact

9 Sep 2020

In today’s rapidly changing world, very few organizations or people can make it alone. At best, orchestrat...

ICT Public Funding innovation ecosystem

Spinverse helped ELISE project to gain 12 M€ funding – project aims to make Europe powerhouse of AI

4 Sep 2020

The goal of the European multi-disciplinary ELISE project, recently funded with 12 M€ by the European Comm...